References
- Papers of special note have been highlighted as:
- ●● of considerable interest
- Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149–160.
- Summary of product characteristics: Remicade. EMA. 2009. [cited 2015 Oct 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf.
- Summary of product characteristics: Humira. EMA. 2009. [cited 2015 Oct 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf.
- Summary of product characteristics: Enbrel. EMA. 2009. [cited 2015 Oct 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf.
- Gibbons LJ, Hyrich KL. Biologic therapy for rheumatoid arthritis clinical efficacy and predictors of response. Biodrugs. 2009;23:111–124.
- Galván-Banqueri M, Marín Gil R, Santos Ramos B, et al. Biological treatments for moderate-to-severe psoriasis: indirect comparison. J Clin Pharm Ther. 2013;38:121–130.
- Murdaca G, Colombo BM, Cagnati P, et al. Update upon efficacy and safety of TNF-α inhibitors. Expert Opin Drug Saf. 2012;11:1–5.
- European Medicines Agency recommends approval of first two monoclonal antibody biosimilars. EMA. 2013. [cited 2015 Oct 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144941.pdf.
- Papamichael K, Van Stappen T, Jairath V, et al. Pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015;42:1158–1169.
- Biogen and Samsung Bioepis announce new data for three anti-TNF biosimilar development candidates at EULAR. 2015 Congress. Biogen. 2015. [cited 2015 Oct 10]. Available from: http://www.businesswire.com/news/home/20150610005239/en/Biogen-Samsung-Bioepis-Announce-Data-Anti-TNF-Biosimilar.
- Knight C, Mauskopf J, Ekelund M, et al. Cost-effectiveness of treatment with etanercept for psoriasis in Sweden. Eur J Health Econ. 2012;13:145–156.
- de Portu D, Giglio M, Altomare G, et al. Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system. Dermatol Ther. 2010;23:S7S13.
- Ferrándiz C, García A, Blasco AJ, et al. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2012;26:768–777.
- Schmitt-Rau K, Rosenbach T, Radtke MA, et al. Cost effectiveness of biological therapy in remission induction of moderate to severe plaque psoriasis. Dermatology. 2010;221:236–242.
- Sizto S, Bansback N, Feldman SR, et al. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol. 2009;160:1264–1272.
- Lekander I, Borgström F, Lysholm J, et al. The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice. Eur J Health Econ. 2013;14:863–873.
- Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis. 2005;64:995–1002.
- Favalli EG, Bugatti S, Biggioggero M, et al. Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. BioMed Res Int. 2014;2014:831603.
- Smith CH, Anstey AV, Barker JNWN, et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis. Br J Dermatol. 2009;161(5):987–1019.
- The National Institute for Health and Care Excellence. Adalimumab, etanercept and infliximab for thr treatment of rheumatoid arthritis. Technology appraisal guidance [Internet]. 2007 [ cited 2015 Jan 21]. Available from: https://www.nice.org.uk/guidance/ta130/resources/adalimumab-etanercept-and-infliximab-for-the-treatment-of-rheumatoid-arthritis-82598187092677
●● Comprehensive review on the three older anti-TNF-α agents for the treatment of rheumatoid arthritis.
- Singh JA, Saag KG, Bridge SLJR, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
- Interchangeability of Biosimilars. FIMEA. 2015. [cited 2015 Oct 10]. Available from: http://www.fimea.fi/whats_new/1/0/are_biosimilars_interchangeable.